Preclinical results and a small Phase Ib trial suggest an oral pill can reduce retinal leakage and swelling in non-proliferative diabetic retinopathy, offering a potential non‑invasive alternative to intraocular injections—larger trials are needed to confirm lasting benefit.
Danegaptide, given orally, reduced blood-retina barrier breakdown, retinal leakage, and edema in preclinical models at levels comparable to injectable anti-VEGF therapies.
The research team recommends larger Phase II trials to determine whether early improvements translate into sustained clinical benefits and to evaluate long-term efficacy.
Diabetic retinopathy affects a large share of people with diabetes and remains a leading cause of blindness in working-age adults. Current standard care for sight‑threatening disease relies on repeated injections of anti‑VEGF drugs into the eye once vision-threatening changes have developed. That treatment approach limits practical options for treating earlier stages of retinal damage in both eyes.
An initial Phase Ib clinical trial enrolled 24 patients with NPDR. Danegaptide was reported to be safe and well tolerated. Biological activity was observed in 55% of participants. Specific signs of activity included:
These human findings indicate the drug can act on the retinal changes present in NPDR, while the comparison with injections is based on the preclinical model outcomes.
If an oral therapy can protect the inner blood-retina barrier and reverse early leakage and edema, treatment could shift earlier in the disease course. An oral pill could be given to both eyes at once and spare many patients the burden and risks of repeated intraocular injections. That could expand options for preventing progression before irreversible vision loss occurs.
The trial was small and early-stage. The main open questions are whether the early anatomical improvements translate into durable clinical outcomes (sustained reduction in progression, preservation of visual acuity) and how the drug performs in larger, more diverse patient groups over longer follow-up.
The study authors and Breye Therapeutics recommend larger Phase II clinical trials to evaluate long-term efficacy, durability of response, and safety in broader populations. Those trials will determine whether danegaptide can replace or complement current injectable therapies for NPDR.
Preclinical data and an initial human study indicate oral danegaptide can target and repair the inner blood-retina barrier, reduce leakage and edema in NPDR, and is well tolerated in the short term. Larger trials are required to confirm whether these early improvements lead to lasting protection of vision.
A 2026 JAMA Ophthalmology trial found gildeuretinol, a modified form of vitamin A, slowed retinal lesion growth by 21. The post A Modified Form of Vitamin A May Finally Slow a Rare Vision Disease appeared first on The Hearty Soul .
Hundreds of Americans are suing the makers of popular GLP-1 weight-loss and diabetes drugs, saying they weren’t adequately warned of the potential danger of vision loss. Diane Wirth, 66, is one of them. She’s been diagnosed with a rare eye injury known as NAION, the acronym for nonarteritic anterior ischemic optic neur
Hundreds of Americans are suing the makers of popular GLP-1 weight-loss and diabetes drugs, saying they weren’t adequately warned of the potential danger of vision loss. Diane Wirth, 66, is one of them. She’s been diagnosed with a rare eye injury known as NAION, the acronym for nonarteritic anterior ischemic optic neur
There's a cheap pill many diabetics are told to '"consider someday." New research says when you start it may matter for your brain.
A new study offers fresh hope that some forms of vision loss, once thought to be permanent, might one day be recoverable.
A familiar diabetes pill could hold the power to slow the biological forces that leave the body increasingly vulnerable to disease as it ages. What if a drug already prescribed to millions of people could do more than control blood sugar? For years, researchers have wondered whether metformin, one of the world’s most w
Loading more related stories...
Open the app view to save this story, compare related coverage, and continue from the same source.